Colchicine for the treatment of COVID19, Cochrane Library
Review (4 RCTs; n=16,013) found colchicine probably has little to no influence on mortality or clinical progression in people hospitalised with moderate to severe COVID ‐19; there is uncertainty about the evidence of its effect in those with asymptomatic infection or mild disease. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - February 7, 2022 Category: Consumer Health News Source Type: news
COVID-19 rapid guideline: managing COVID-19 [NG191], NICE (updated 1st December 2021)
This guideline covers the management of COVID-19 for children, young people and adults in all care settings. It brings together our existing recommendations on managing COVID-19, and new recommendations on therapeutics, so that healthcare staff and those planning and delivering services can find and use them more easily.
We are continually monitoring the evidence and updating the guideline as new information emerges.
On 1 December, we updated existing recommendations on colchicine. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - December 2, 2021 Category: Consumer Health News Source Type: news
' Misleading' Results in Colchicine COVID-19 Trials Meta-Analysis'Misleading' Results in Colchicine COVID-19 Trials Meta-Analysis
In a meta-analysis of six studies evaluating colchicine as a COVID-19 treatment, the anti-inflammatory drug for acute gout attacks did not appear to improve outcomes for patients.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - November 23, 2021 Category: Drugs & Pharmacology Tags: Rheumatology News Source Type: news
Anti-inflammatory drug used to treat gout does NOT prevent hospitalization or death from COVID-19
A study performed by an Indian research team finds that the gout drug colchicine does not have the ability to reduce the risk of severe complications from COVID-19. (Source: the Mail online | Health)
Source: the Mail online | Health - November 22, 2021 Category: Consumer Health News Source Type: news
Corrigendum to: Pathogenic characteristics and treatment in 43 cases of acute colchicine poisoning - Lu X, Liu Y, Wang C, Dong J, Bai L, Zhang C, Zhang R, Sun C, Qiu Z.
[This corrects the article DOI: 10.1093/toxres/tfab074.].
In the original publication of this article, there were errors within the data of Table 1.
Language: en... (Source: SafetyLit)
Source: SafetyLit - November 8, 2021 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news
Gloperba (Colchicine Oral Solution) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 1, 2021 Category: Drugs & Pharmacology Source Type: news
Featured review: Colchicine for Covid
Is colchicine an effective treatment for people with COVID-19?Colchicine was debated to be a potential treatment option for COVID-19, hoping that the medication ’s anti-inflammatory properties could prevent or reduce a dysregulated immune response.Although there are completed studies without publication and diverse ongoing studies that could change our findings, the current evidence taken from 3 studies is moderate that colchicine makes no difference for people with moderate to severe disease. The safety of the medication remained unclear- given the restricted dosage range and the inconsistent reporting of (serious) adve...
Source: Cochrane News and Events - September 30, 2021 Category: Information Technology Authors: Lydia Parsonson Source Type: news
Gout Pharmacotherapy in Cardiovascular Diseases Gout Pharmacotherapy in Cardiovascular Diseases
This review examines the utility of current gout therapies in the treatment and prevention of cardiovascular disease, including allopurinol, febuxostat, and colchicine.American Journal of Cardiovascular Drugs (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 30, 2021 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
Two Swings, Two Misses With Colchicine, Vascepa in COVID-19 Two Swings, Two Misses With Colchicine, Vascepa in COVID-19
The study cohorts varied from healthcare and public workers at high risk for infection to individuals already hospitalized with COVID-19.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 1, 2021 Category: Consumer Health News Tags: Cardiology News Source Type: news
Colchicine Effective Regardless of ACS History, Timing: LoDoCo2 Colchicine Effective Regardless of ACS History, Timing: LoDoCo2
The results contrast with those from another subanalysis, in which greater benefits were observed with earlier administration of the repurposed gout medication.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - August 23, 2021 Category: Neurology Tags: Cardiology News Source Type: news
Pathogenic characteristics and treatment in 43 cases of acute colchicine poisoning - Lu X, Liu Y, Wang C, Dong J, Bai L, Zhang C, Zhang R, Sun C, Qiu Z.
Colchicine poisoning is complicated and has a high mortality rate. The aim of this study was to identify the pathogenic characteristics of colchicine poisoning cases and to propose a comprehensive treatment procedure. A total of 43 patients were divided in... (Source: SafetyLit)
Source: SafetyLit - August 23, 2021 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news
Colchicine and the Heart Colchicine and the Heart
Recent studies have demonstrated the potential of colchicine in a range of cardiovascular conditions. This review summarizes the current data supporting its efficacy and safety.Europace (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 23, 2021 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
Regulatory nod for conducting clinical trials of Colchicine on COVID-19 patients: CSIR
CSIR institutes' partners in this important clinical trial are the CSIR-IICT, Hyderabad and CSIR-IIIM, Jammu. (Source: The Economic Times)
Source: The Economic Times - June 12, 2021 Category: Consumer Health News Source Type: news
Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial, The Lancet Respiratory Medicine
In patients ≥40 with Covid-19 and ≥1 high-risk characteristic (n=4488), colchicine (0.5mg twice daily for 3 days, then once daily for 27 days) was not associated with a statistically significant reduction in death or Covid-19 hospital admission (4.7% v 5.8% placebo; p=0.081). (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - June 1, 2021 Category: Consumer Health News Source Type: news
Managing COVID-19 [NG191], NICE (updated 27th May 2021)
New recommendations have been added on colchicine to treat COVID-19 and existing recommendations on remdesivir for COVID-19 pneumonia have been updated. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - May 28, 2021 Category: Consumer Health News Source Type: news
